COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUmiT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00771264
Recruitment Status : Completed
First Posted : October 13, 2008
Results First Posted : September 21, 2010
Last Update Posted : April 18, 2012
Information provided by (Responsible Party):
Uroplasty, Inc

Brief Summary:
The purpose of this study is to demonstrate superiority of percutaneous posterior tibial nerve stimulation (PTNS) therapy compared to sham therapy for the treatment of patients with overall bladder (OAB) symptoms.

Condition or disease Intervention/treatment Phase
Overactive Bladder Device: Urgent PC Neuromodulation System Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : September 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Urgent PC Device: Urgent PC Neuromodulation System
The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).

No Intervention: Sham / Placebo

Primary Outcome Measures :
  1. The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting "Moderately" or "Markedly Improved" Responses on the GRA After 12 Interventions of Randomized Therapy, in an Intent to Treat Analysis. [ Time Frame: 13 weeks ]
    A responder was defined as reporting bladder symptoms as moderately or markedly improved on a 7-level GRA at week 13 after completing 12, 30-minute, consecutive weekly intervention sessions.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women and men >18 years of age
  • A score of > 4 on the OAB-q short form for urgency (question 1)
  • Average urinary frequency > 10 times in one 24 hour day based on a 3-day voiding diary
  • Self-reported bladder symptoms present > 3 months
  • Self-reported failed conservative care (i.e., dietary restriction, fluid restriction, bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.)
  • Off all antimuscarinics for at least 2 weeks prior to enrollment
  • Capable of giving informed consent
  • Ambulatory and able to use a toilet independently, without difficulty
  • Capable and willing to follow all study-related procedures

Exclusion Criteria:

  • Pregnant as confirmed by urine pregnancy test, or plans to become pregnant during the study period
  • Neurogenic bladder
  • Botox use in bladder or pelvic floor muscles in the past year
  • Pacemakers or implantable defibrillators
  • Primary complaint of stress urinary incontinence
  • Current urinary tract infection (UTI)
  • Current vaginal infection
  • Current use of InterStim
  • Current use of Bion
  • Current use of TENS in the pelvic region, back or legs
  • Previously been treated with PTNS
  • Use of investigational drug/device therapy within the past 4 weeks
  • Participating or have participated within the past 4 weeks in any clinical investigation involving or impacting gynecologic, urinary or renal function
  • Deemed unsuitable for enrollment in study by the investigators based on subjects' history or physical examination (including bleeding disorders or anticoagulant medications, and peripheral neuropathy)
  • Subjects with nerve damage that would impact either percutaneous tibial nerve or pelvic floor function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00771264

Layout table for location information
United States, California
Gregory L. Davis, M.D., FACOG, Inc.
Chico, California, United States, 95928
United States, Connecticut
Greenwich Urological Associates, P.C.
Greenwich, Connecticut, United States, 06830
United States, Florida
Specialists in Urology
Naples, Florida, United States, 34102
United States, Michigan
Mercy Health Partners at the Lakes
Muskegon, Michigan, United States, 49444
Beaumont Hospital
Royal Oak, Michigan, United States, 48703
United States, Minnesota
Grand Rapids Women's Health DBA Female Pelvic Medicine & Urogynecology Institue of Michigan
Grand Rapids, Minnesota, United States, 49503
Uroplasty, Inc
Minnetonka, Minnesota, United States, 55343
Beaumont Hospital
Royal Oak, Minnesota, United States, 48073
United States, Nebraska
Urology Health Center, PC
Fremont, Nebraska, United States, 68025
United States, New York
Capital Region Urological Surgeons, PLLC
Albany, New York, United States, 12208
Central Missouri Women's Healthcare, LLC
White Plains, New York, United States, 10604
United States, North Carolina
Alliance Urology Specialists
Greensboro, North Carolina, United States, 27403
United States, Oklahoma
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Virginia
Virginia Urology
Richmond, Virginia, United States, 23235
United States, Washington
Athena Urology
Issaquah, Washington, United States, 98027
Sponsors and Collaborators
Uroplasty, Inc
Layout table for additonal information
Responsible Party: Uroplasty, Inc Identifier: NCT00771264    
Other Study ID Numbers: UPC082008
First Posted: October 13, 2008    Key Record Dates
Results First Posted: September 21, 2010
Last Update Posted: April 18, 2012
Last Verified: April 2012
Keywords provided by Uroplasty, Inc:
Overactive Bladder
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms